Home / Market News / $BMY

$BMY news and market catalysts

The 42 most recent market catalysts affecting $BMY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

42 catalysts 10 high impact 26 bullish 9 bearish Pharmaceuticals
Nov 18, 2026 Corporate Catalyst Neutral Impact 75
Bristol Myers Squibb Presents Phase 3 Data for KarXT in Alzheimer's-Related Psychosis
Bristol Myers Squibb announced the presentation of initial Phase 3 data for KarXT, a drug targeting psychosis associated with Alzheimer's disease. This is a significant milestone a…
Nov 6, 2026 Corporate Catalyst Neutral Impact 55
Bristol Myers Squibb Presents 56-Week Phase 3 Data for Camzyos in Pediatric Patients with Symptomatic oHCM
Bristol Myers Squibb announced 56-week Phase 3 results for Camzyos in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data showed consistent…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Polaris Rx Selected to Dispense Bristol Myers Squibb's ZENBEXUS™
Bristol Myers Squibb (BMY) has announced a distribution agreement with Polaris Rx for its new multiple myeloma drug, ZENBEXUS™. This is a significant step in the commercial rollout…
Nov 4, 2026 Corporate Catalyst Bullish Impact 85
Bristol Myers Squibb and SystImmune Report Positive Phase 3 Results for Iza-Bren in Breast Cancer
Bristol Myers Squibb and SystImmune reported highly positive Phase 3 results for iza-bren in HR+/HER2- breast cancer, meeting its primary endpoint with a 59% reduction in disease p…
Nov 2, 2026 Corporate Catalyst Bearish Impact 75
Bristol Myers Squibb Updates 2026 Financial Guidance
Bristol Myers Squibb has revised its 2026 financial outlook, increasing its revenue forecast while simultaneously decreasing its non-GAAP EPS guidance. The primary driver for the E…
Oct 30, 2026 Corporate Catalyst Bearish Impact 55
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $63
Goldman Sachs has revised its price target for Bristol-Myers Squibb (BMY) down to $61 from $63. This analyst action reflects a re-evaluation of the biopharmaceutical company's pros…
Oct 29, 2026 Corporate Catalyst Neutral Impact 75
Bristol Myers Squibb Reports Third Quarter 2026 Financial Results
Bristol Myers Squibb has released its third-quarter 2026 financial results, a routine but critical disclosure for publicly traded companies. This filing provides investors with a c…
Oct 26, 2026 Corporate Catalyst Bullish Impact 85
Bristol Myers Squibb and SystImmune Announce Positive Phase 3 Results for Izalontamab Brengitecan in NSCLC
Bristol Myers Squibb and SystImmune announced positive interim Phase 3 results for izalontamab brengitecan, an antibody-drug conjugate, in previously-treated EGFR-mutated non-small…
Oct 26, 2026 Corporate Catalyst Bearish Impact 55
Piper Sandler Adjusts Price Target on Bristol Myers Squibb
Piper Sandler, a financial services firm, has adjusted its price target for Bristol Myers Squibb (BMY) from $82 to $78. This change reflects a revised valuation outlook by the firm…
Oct 23, 2026 Corporate Catalyst Neutral Impact 75
Bristol Myers Squibb Reports Interim Phase 1 Data for CAR T-Cell Therapy in Multiple Sclerosis
Bristol Myers Squibb announced interim Phase 1 results for its CAR T-cell therapy, zola-cel, for multiple sclerosis. The data showed all 60 patients at the second dose level remain…
Oct 23, 2026 Corporate Catalyst Bullish Impact 65
Bristol Myers Squibb Expands AI Partnerships with Tempus AI and Pathos AI
Bristol Myers Squibb (BMY) has announced two significant AI partnerships. First, a multi-year agreement with Tempus AI (TEMP) for oncological data and access to its Lens Platform, …
Oct 12, 2026 Corporate Catalyst Bullish Impact 85
Bristol-Myers Squibb shares are trading higher after the company announced results from unit RayzeBio's ACTION-1 trial of RYZ101, which study met its primary endpoint with statistically significant and clinically meaningful improvement in progression-free survival with consistent safety results.
This headline represents a significant positive catalyst for Bristol-Myers Squibb. The successful ACTION-1 trial for RYZ101, a radiopharmaceutical for neuroendocrine tumors, indica…
Oct 12, 2026 Corporate Catalyst Bullish Impact 85
Why Is Bristol Myers Squibb Stock Gaining Monday?
Bristol Myers Squibb (BMY) announced successful interim results from its ACTION-1 Phase 3 trial for RYZ101, showing statistically significant improvement in progression-free surviv…
Oct 12, 2026 Corporate Catalyst Bullish Impact 75
Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile
Bristol Myers Squibb's RayzeBio unit announced that its ACTION-1 trial for RYZ101 met its primary endpoint, demonstrating a statistically significant and clinically meaningful impr…
Oct 12, 2026 Corporate Catalyst Bullish Impact 75
Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial
Bristol Myers Squibb reported positive topline results for its drug admilparant in a Phase 3 trial for Idiopathic Pulmonary Fibrosis (IPF). The 60 mg dose demonstrated a statistica…
Oct 8, 2026 Corporate Catalyst Bullish Impact 75
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb (BMY) announced highly positive Phase 3 results for Zenbexus (iberdomide) in multiple myeloma, demonstrating a 51% reduction in the risk of disease progression…
Oct 8, 2026 Corporate Catalyst Bearish Impact 55
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53
Cantor Fitzgerald analyst Carter Gould has maintained a 'Neutral' rating on Bristol-Myers Squibb (BMY) but significantly lowered the price target from $59 to $53. This action indic…
Oct 5, 2026 Corporate Catalyst Bearish Impact 75
Bristol-Myers Squibb shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $73 to $59.
This downgrade by Leerink Partners is a significant negative catalyst for Bristol-Myers Squibb (BMY). Analyst downgrades, especially with substantial price target reductions, often…
Oct 5, 2026 Corporate Catalyst Bearish Impact 65
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59
Leerink Partners analyst David Risinger downgraded Bristol-Myers Squibb (BMY) from 'Outperform' to 'Market Perform' and significantly lowered the price target from $73 to $59. This…
Sep 18, 2026 Market Technicals Neutral Impact 55
9 Health Care Stocks Whale Activity In Today’s Session
The filing reports on 'whale' options activity, which refers to large-volume trades by institutional investors or high-net-worth individuals. This activity is significant because i…
Sep 17, 2026 Corporate Catalyst Bullish Impact 65
Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years
Bristol Myers Squibb released long-term results from its POETYK PsA-2 trial for Sotyktu, showing durable efficacy and a consistent safety profile over two years for active psoriati…
Sep 17, 2026 Corporate Catalyst Bullish Impact 65
Bristol Myers Squibb Announces Two-Year Results From Its Phase 3 POETYK PSA-2 Study Showing Durable Efficacy And A Consistent Safety Profile For Sotyktu In Adults With Active Psoriatic Arthritis; Data Build On The Proven Efficacy And Safety Of Sotyktu
Bristol Myers Squibb released two-year data from its Phase 3 POETYK PsA-2 study for Sotyktu, showing sustained efficacy and a favorable safety profile in adults with active psoriat…
Sep 8, 2026 Corporate Catalyst Bullish Impact 75
Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients
Bristol Myers Squibb's announcement of positive Phase 2 trial results for arlo-cel is a significant corporate catalyst. The experimental cell therapy showed promise in heavily pret…
Sep 8, 2026 Corporate Catalyst Bearish Impact 75
Bristol-Myers Squibb shares are trading lower after the company announced that its multiple myeloma candidate arlocabtagene autoleucel met primary and secondary endpoints in its phase II QUINTESSENTIAL trial. Investors may be taking pause after the results following an approximately 43% share price gain over the past year.
This headline presents a classic 'buy the rumor, sell the news' scenario for Bristol-Myers Squibb. Despite arlocabtagene autoleucel meeting its endpoints, the stock is trading lowe…
Sep 4, 2026 Corporate Catalyst Bearish Impact 75
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
The filing highlights that Bristol Myers Squibb and Novartis withheld crucial safety information regarding their CAR-T clinical trials for autoimmune diseases, including trial free…
Aug 14, 2026 Corporate Catalyst Bullish Impact 85
Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment
Bristol Myers Squibb (BMY) secured accelerated FDA approval for Zenbexus (iberdomide) for adult patients with multiple myeloma. This is a significant positive catalyst as Zenbexus …
Aug 13, 2026 Corporate Catalyst Bullish Impact 75
Bristol-Myers Squibb Receives FDA Approval For ZENBEXUS In Combination With Daratumumab And Hyaluronidase-fihj and Dexamethasone For Patients with Multiple Myeloma
Bristol Myers Squibb received FDA approval for ZENBEXUS, a new drug for multiple myeloma. This is significant because ZENBEXUS is the first FDA-approved CELMoD, representing a new …
Aug 10, 2026 Corporate Catalyst Bullish Impact 55
Bristol Myers Squibb To Invest $2.3B In Houston Manufacturing Campus, Creating Nearly 500 Jobs
Bristol Myers Squibb is investing $2.3 billion in a new, state-of-the-art manufacturing campus in Houston, Texas, which will create nearly 500 skilled jobs. This investment is part…
Aug 5, 2026 Corporate Catalyst Bearish Impact 75
Bristol Myers Squibb shares are trading lower after reports suggesting that the company didn't have any merger discussions with AstraZeneca.
The headline indicates that Bristol Myers Squibb (BMY) shares are trading lower because reports of a potential merger with AstraZeneca (AZN) have been debunked. Merger speculation …
Aug 3, 2026 Corporate Catalyst Neutral Impact 90
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
A media report over the weekend indicated that AstraZeneca and Bristol Myers Squibb are in talks for a massive $400 billion merger. This potential deal is highly significant as bot…
Aug 3, 2026 Corporate Catalyst Bullish Impact 95
Why Is Bristol-Myers Squibb Stock Surging Monday?
Bristol-Myers Squibb's stock is surging due to reports of advanced merger talks with AstraZeneca, potentially creating a $400 billion pharmaceutical giant. This news is a major cor…
Aug 3, 2026 Corporate Catalyst Bullish Impact 95
Bristol Myers Squibb shares are trading higher following reports suggesting the company is in discussions to merge with AstraZeneca.
A potential merger between Bristol Myers Squibb and AstraZeneca would be a major corporate catalyst, driving significant volatility and upward pressure on BMY shares due to an expe…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Bristol-Myers Squibb, Raises Price Target to $73
JP Morgan analyst Chris Schott maintained an 'Overweight' rating on Bristol-Myers Squibb (BMY) and raised the price target from $67 to $73. This action signals continued confidence…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $65
Wells Fargo analyst Mohit Bansal maintained an 'Equal-Weight' rating on Bristol-Myers Squibb (BMY) but raised the price target from $60 to $65. This action signals a slightly impro…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $75
Guggenheim analyst Seamus Fernandez maintained a 'Buy' rating on Bristol-Myers Squibb (BMY) and raised the price target from $72 to $75. This action reflects an analyst's updated p…
Jul 30, 2026 Corporate Catalyst Bullish Impact 85
Bristol-Myers Boosts 2026 Guidance on Portfolio Strength
Bristol-Myers Squibb's Q2 2026 earnings and sales significantly surpassed analyst expectations, primarily due to strong performance in its 'Growth Portfolio' products like Opdivo Q…
Jul 30, 2026 Macro/Central Bank Bullish Impact 65
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
This filing provides a comprehensive daily market recap, with Bristol-Myers Squibb's strong earnings serving as a key corporate catalyst. The broader market saw gains, particularly…
Jul 30, 2026 Corporate Catalyst Bullish Impact 85
Bristol-Myers Squibb Q2 Adj. EPS $2.04 Beats $1.59 Estimate, Sales $12.973B Beat $11.745B Estimate
This headline is a significant corporate catalyst for Bristol-Myers Squibb (BMY). The substantial beat on both adjusted EPS and sales indicates better-than-expected performance, li…
Jul 20, 2026 Corporate Catalyst Neutral Impact 75
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI
Bristol Myers Squibb (BMY) is making a substantial investment in AI by deploying NVIDIA's (NVDA) DGX SuperPOD, creating the most powerful AI infrastructure in the life sciences. Th…
Jul 20, 2026 Corporate Catalyst Bullish Impact 75
Bristol Myers Squibb To Expand Compute Infrastructure To Deploy NVIDIA DGX SuperPOD With DGX Vera Rubin NVL72 Systems
This headline indicates a substantial investment by Bristol Myers Squibb (BMY) into cutting-edge AI infrastructure, specifically NVIDIA's DGX SuperPOD. This move is a strong positi…
Jul 13, 2026 Corporate Catalyst Bullish Impact 75
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment
Bristol Myers Squibb announced that the FDA accepted its New Drug Application for mezigdomide, an oral therapy for multiple myeloma, with a target action date in 2027. This is a si…
Jul 13, 2026 Corporate Catalyst Bullish Impact 75
Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027
Bristol Myers Squibb (BMY) announced the FDA's acceptance of its New Drug Application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refrac…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.